Taimed

    [td_text_with_title custom_title=”Company Description”]

    TaiMed Biologics was formed on September 4, 2007 to realize the vision of creating a world-class, innovation-based biotechnology company that will satisfy the unmet medical needs of patients around the world.

    The company signed an agreement with Genentech for the licensing of Ibalizumab shortly after its formation. This drug candidate, also known as TMB-355, is a proprietary humanized anti-CD4 monoclonal antibody for the treatment of HIV/AIDS. A phase-2b clinical trial is currently underway and we expect the trial to be completed in Q1 2011.

    TaiMed Biologics has made much progress in its short existence. An outstanding management team with industry experience has been assembled in both Taiwan and the US. TMB is committed to evaluating new business development opportunities.

    In Q4 of 2008, TMB in-licensed Tamiphosphor, a neuraminidase inhibitor for the treatment of influenza, from Academia Sinica in Taiwan and has taken that program forward. In early 2009, drug synthesis work has been conducted as well as a collaboration with NIH has been established for cross resistance testing. In addition, in collaboration with the Aaron Diamond AIDS Research Center, the development of Ibalizumab for prevention of HIV infection will be explored in a phase 1 trial in 2H 2010.  This project has received grant funding from the Bill and Melinda Gates Foundation.

    TaiMed Biologics is committed to conducting business with integrity and passion. We remain to be forward-thinking and utilize our resources wisely and efficiently in order to meet our long-term objectives.

    [/td_text_with_title]
    Drugs

    Ibalizumab

    Ibalizumab is an investigational drug that is being studied for the treatment of HIV infection. Ibalizumab belongs to a class (group) of HIV drugs called entry and fusion inhibitors. Entry and fusion inhibitors block HIV from getting into and infecting certain cells of the immune system. This prevents HIV from multiplying and can reduce the amount of [...]
    0 comments
    [td_text_with_title custom_title=”Latest post”]

    Posts not found

    [/td_text_with_title]